ExonHit launches Alzheimer's blood test for research use
This article was originally published in Clinica
ExonHit Therapeutics has launched its Alzheimer’s blood test, AclarusDx. The product is now available for research use only for pharmaceutical companies and academic centres conducting clinical trials in the disorder. ExonHit (Paris, France) will process blood samples at its GLP-compliant labs in the US. The company plans to CE mark the test for sale in Europe in the fourth quarter of 2010, with a European launch following in the first quarter of 2011. AclarusDx analyses whether messenger RNA from a patient's blood sample matches a molecular profile that is specific to Alzheimer's disease.